医学
高眼压
青光眼
眼压
眼科
临床试验
随机对照试验
生活质量(医疗保健)
开角型青光眼
外科
内科学
护理部
作者
Gus Gazzard,Evgenia Konstantakopoulou,David Garway-Heath,Mariam Adeleke,Victoria Vickerstaff,Gareth Ambler,Rachael Hunter,Catey Bunce,Neil Nathwani,Keith Barton
出处
期刊:Ophthalmology
[Elsevier]
日期:2023-02-01
卷期号:130 (2): 139-151
被引量:8
标识
DOI:10.1016/j.ophtha.2022.09.009
摘要
The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial has shown selective laser trabeculoplasty (SLT) to be clinically and cost-effective as a primary treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT) at 3 years. This article reports health-related quality of life (HRQoL) and clinical effectiveness of initial treatment with SLT compared with intraocular pressure (IOP)-lowering eye drops after 6 years of treatment.Prospective, multicenter randomized controlled trial.Treatment-naive eyes with OAG or OHT initially treated with SLT or IOP-lowering drops.Patients were allocated randomly to initial SLT or eye drops. After the initial 3 years of the trial, patients in the SLT arm were permitted a third SLT if necessary; patients in the drops arm were allowed SLT as a treatment switch or escalation. This study is registered at controlled-trials.com (identifier, ISRCTN32038223).The primary outcome was HRQoL at 6 years; secondary outcomes were clinical effectiveness and adverse events.Of the 692 patients completing 3 years in the LiGHT Trial, 633 patients (91.5%) entered the extension, and 524 patients completed 6 years in the trial (82.8% of those entering the extension phase). At 6 years, no significant differences were found for the EuroQol EQ-5D 5 Levels, Glaucoma Utility Index, and Glaucoma Quality of Life-15 (P > 0.05 for all). The SLT arm showed better Glaucoma Symptom Scale scores than the drops arm (83.6 ± 18.1 vs. 81.3 ± 17.3, respectively). Of eyes in the SLT arm, 69.8% remained at or less than the target IOP without the need for medical or surgical treatment. More eyes in the drops arm exhibited disease progression (26.8% vs. 19.6%, respectively; P = 0.006). Trabeculectomy was required in 32 eyes in the drops arm compared with 13 eyes in the SLT arm (P < 0.001); more cataract surgeries occurred in the drops arm (95 compared with 57 eyes; P = 0.03). No serious laser-related adverse events occurred.Selective laser trabeculoplasty is a safe treatment for OAG and OHT, providing better long-term disease control than initial drop therapy, with reduced need for incisional glaucoma and cataract surgery over 6 years.
科研通智能强力驱动
Strongly Powered by AbleSci AI